Business Wire

UNIVERSITY-OF-OULU

30.6.2020 06:07:12 CEST | Business Wire | Press release

Share
University of Oulu: Butterfly Wings As Inspiration for More Effective Solar Panels

The color of butterflies is mainly attributed to structural color as a result of diffraction of natural light. However, black color denotes trapping of sunlight within the butterfly scales. In some extreme cases, a butterfly will be rapidly de-iced through light-heat conversion within black scales on wings. Inspired by such a natural light harvesting process, scientists in the University of Oulu, Finland, research unit NANOMO carefully examined nanostructures of black scales obtained from different butterflies and assessed their light trapping abilities when placed on Si-based solar panels.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200629005043/en/

Even with apparently the same dark color, butterfly scales have varied nanostructures depending on their species. For example, the morphology of Ornithoptera priamus scale consists of parallel V-shaped gullies formed between two ridges and connected by thin layers. This is very different from the scale structure of other three species, Tirumala limniace, Graphium doson, and Papilio protenor cramer, where the structures consist of round ridges spaced by arrays of 1, 2, and 3 holes. Correspondingly, light reflection on the black scales differs, with the one on the black part of Ornithoptera priamus owing minimum values ranging from 1-5% at the visible light region.

Using these structures as antireflective patterns will help sunlight harvesting on Si based photovoltaics. Computer simulated results showed that after placing these nanostructures on Si solar panels, surface backscattering decreased substantially. The scale structure of Ornithoptera priamus gave the best antireflection. Light reflection decreased from more than 35% on bare Si panel down to less than 5%. As a result, the short-circuit current, i.e. the largest current that can be obtained from the photovoltaic cell, was increased by 66%. Experimental realizations of such a strategy have also been proposed.

The latest research progress continues the world-leading role of NANOMO group in biomimicry. The unit pioneers in applying fundamental concepts in physics to applied photonics and solar energy harvesting. The research was coordinated by Professors Wei Cao and Marko Huttula, University of Oulu.

Considering the large volume of Si solar panels in use, it is foreseen that the butterfly wings can provide a major contribution to clean energy production.

Article:
Zhongjia Huang, Xinying Shi, Gang Wang, Petri Leukkunen, Marko Huttula, Wei Cao:
Antireflective design of Si-based photovoltaics via biomimicking structures on black butterfly scales, Solar Energy, Volume 4. DOI: https://doi.org/10.1016/j.solener.2020.05.031 sciencedirect.com 2020
https://www.sciencedirect.com/science/article/pii/S0038092X2030520X

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Gurobi Appoints Dr. Pascal Van Hentenryck to Lead AI Innovation Lab17.2.2026 15:00:00 CET | Press release

Renowned optimization and AI technologies leader to advance hybrid approaches for demanding decision challenges. Gurobi Optimization, LLC, the leader in decision intelligence technology, is pleased to announce that Dr. Pascal Van Hentenryck has joined the company as head of the Gurobi AI Innovation Lab (GAIL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217170385/en/ Dr. Pascal Van Hentenryck, Head of AI Innovation Lab, Gurobi Optimization As part of Gurobi’s long-term product and technology strategy, the Gurobi AI Innovation Lab is a focused Research & Development initiative dedicated to advancing the combination of multiple AI technologies with optimization to solve complex, large-scale, and time-critical decision problems. “Pascal brings exceptional leadership across mathematical optimization and complementary AI technologies,” said Dr. Oliver Bastert, CTO, Gurobi Optimization. “While mathematical optimization remai

Esri and Pix4D Launch Real-Time Terrestrial Mapping Workflow17.2.2026 14:00:00 CET | Press release

Alliance Brings Seamless Integration of Asset Data into ArcGIS for PIX4Dcatch Users Pix4D joins with Esri to launch new terrestrial scanning workflow for infrastructure-focused organizations. Esri and Pix4D workflow lets field teams capture accurate 3D models and augmented reality using PIX4Dcatch app data integrated directly into ArcGIS Online in real time. New integration enables users to document subsurface assets with seamless precision. Workflow brings high-fidelity, georeferenced documentation and instant verification to the project lifecycle for improved accuracy. Explore the PIX4Dcatch app and publish 3D data to ArcGIS Online. Esri, the global leader in geographic information system (GIS) technology, has launched a terrestrial mapping workflow with Pix4D. A Switzerland-based photogrammetry software company, Pix4D specializes in mobile reality capture and site-digitization. The combined workflow allows field teams to capture and process asset data and manage it within ArcGIS, Es

Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample17.2.2026 14:00:00 CET | Press release

Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, for certain foundational CRISPR-Cas9 intellectual property for use in NGS library preparation. While CRISPR-Cas9 technologies are most commonly associated with their unique ability to find and cut for genome editing, Watchmaker is leveraging it in a fundamentally different way: as a programmable, stoichiometric binding tool to address one of the most persistent and under-optimized steps in NGS workflows – library normalization. “Normalization has quietly become a bottleneck as sequencing throughput has scaled,” said Brian Kudlow, CSO and Founderat Watchmaker Genomics. “This license gives us the freedom to rethink normalization from first principles, using CRISPR-Cas9 in a way that’s orthogonal to editing but highly aligned with modern sequenc

Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression17.2.2026 12:30:00 CET | Press release

Two highly statistically significant positive Phase 3 trials confirm highly differentiated profile for COMP360, demonstrating a level of clinical effect that has historically been extremely difficult to achieve in TRDCOMP360 is the first classic psychedelic1 to consistently achieve a highly statistically significant result and clinically meaningful effect, with a generally well-tolerated and safe profileIn COMP006, two doses of COMP360 25 mg versus 1 mg demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity as measured by MADRS2 with a mean difference of -3.8 comparing 25 mg to 1 mg (p<0.001)3Clinically meaningful reduction in MADRS (≥ 25%) observed in significant number of participants in 25mg arm of both trials with 25% in COMP005 and 39% in COMP006Statistically significant rapid onset from the day following administration maintained at all measured timepoints through Week 6 in both clinical trials in the 25 mg armIn COMP005, participa

BeOne Medicines to Present at Upcoming Investor Conferences17.2.2026 12:00:00 CET | Press release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in fireside chats at four upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 am ET; Leerink Global Healthcare Conference on Monday, March 9, 2026 at 11:20 am ET; Citizens Life Sciences Conference on Tuesday, March 10, 2026 at 9:35 am ET; and Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 3:00 pm ET Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye